WallStSmart

Microchip Technology Inc (MCHP)vsZepp Health Corp (ZEPP)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Microchip Technology Inc generates 1589% more annual revenue ($4.37B vs $258.90M). MCHP leads profitability with a -1.6% profit margin vs -15.5%. ZEPP earns a higher WallStSmart Score of 41/100 (D).

MCHP

Hold

37

out of 100

Grade: F

Growth: 4.0Profit: 3.5Value: 5.0Quality: 6.0
Piotroski: 3/9Altman Z: 1.53

ZEPP

Hold

41

out of 100

Grade: D

Growth: 4.7Profit: 2.0Value: 6.7Quality: 5.0
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MCHPOvervalued (-6.4%)

Margin of Safety

-6.4%

Fair Value

$75.87

Current Price

$89.44

$13.57 premium

UndervaluedFair: $75.87Overvalued
ZEPPUndervalued (+57.2%)

Margin of Safety

+57.2%

Fair Value

$56.09

Current Price

$16.76

$39.33 discount

UndervaluedFair: $56.09Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MCHP1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
15.6%8/10

15.6% revenue growth

ZEPP2 strengths · Avg: 10.0/10
Price/BookValuation
1.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
43.0%10/10

Revenue surging 43.0% year-over-year

Areas to Watch

MCHP4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.534/10

Distress zone — elevated risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-1.1%2/10

ROE of -1.1% — below average capital efficiency

EPS GrowthGrowth
-81.6%2/10

Earnings declined 81.6%

ZEPP4 concerns · Avg: 2.0/10
Market CapQuality
$245.12M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-17.2%2/10

ROE of -17.2% — below average capital efficiency

EPS GrowthGrowth
-68.1%2/10

Earnings declined 68.1%

Profit MarginProfitability
-15.5%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : MCHP

The strongest argument for MCHP centers on Revenue Growth. Revenue growth of 15.6% demonstrates continued momentum. PEG of 1.11 suggests the stock is reasonably priced for its growth.

Bull Case : ZEPP

The strongest argument for ZEPP centers on Price/Book, Revenue Growth. Revenue growth of 43.0% demonstrates continued momentum.

Bear Case : MCHP

The primary concerns for MCHP are Altman Z-Score, Piotroski F-Score, Return on Equity.

Bear Case : ZEPP

The primary concerns for ZEPP are Market Cap, Return on Equity, EPS Growth.

Key Dynamics to Monitor

MCHP profiles as a growth stock while ZEPP is a hypergrowth play — different risk/reward profiles.

ZEPP carries more volatility with a beta of 1.77 — expect wider price swings.

ZEPP is growing revenue faster at 43.0% — sustainability is the question.

Monitor SEMICONDUCTORS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZEPP scores higher overall (41/100 vs 37/100) and 43.0% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Microchip Technology Inc

TECHNOLOGY · SEMICONDUCTORS · USA

Microchip Technology Inc. is a publicly-listed American corporation that manufactures microcontroller, mixed-signal, analog and Flash-IP integrated circuits.

Zepp Health Corp

TECHNOLOGY · CONSUMER ELECTRONICS · China

Zepp Health Corporation, an activity and biometric data-driven company, develops, manufactures and sells smart wearable technology devices in the People's Republic of China. The company is headquartered in Hefei, the People's Republic of China.

Want to dig deeper into these stocks?